A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
Stopped In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to safety concerns.
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG: Carboplatin
- DRUG: Paclitaxel
- DRUG: MEDI-575
Sponsor
MedImmune LLC